Evidence map›Paper›PMID 26831660›Full record

Trial reportTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.

Petra Leidinger, Martin Hart, Christina Backes, Stefanie Rheinheimer, Bastian Keck, Bernd Wullich, Andreas Keller, Eckart Meese

Abstract readClinical TrialComparative Study
PubMed Publisher
In one paragraph

Trial report in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
6.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 52 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. miR-34a as hub of T cell regulation networks.Journal for immunotherapy of cancer · 2019
    Article
  17. Article
  18. Article
  19. Circulating miR-20a and miR-26a as Biomarkers in Prostate CancerAsian Pacific journal of cancer prevention : APJCP · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Petra LeidingerInstitute of Human Genetics, Saarland University, Human Genetics, Building 60, 66421, Homburg, Germany.
Martin HartInstitute of Human Genetics, Saarland University, Human Genetics, Building 60, 66421, Homburg, Germany.
Christina BackesChair for Clinical Bioinformatics, Saarland University, Saarbrücken, Germany.
Stefanie RheinheimerInstitute of Human Genetics, Saarland University, Human Genetics, Building 60, 66421, Homburg, Germany.
Bastian KeckDepartment of Urology, University Hospital Erlangen, 91054, Erlangen, Germany.
Bernd WullichDepartment of Urology, University Hospital Erlangen, 91054, Erlangen, Germany.
Andreas KellerChair for Clinical Bioinformatics, Saarland University, Saarbrücken, Germany.
Eckart MeeseInstitute of Human Genetics, Saarland University, Human Genetics, Building 60, 66421, Homburg, Germany. hgemee@uks.eu.
Saarland University · DEUniversitätsklinikum Erlangen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the benefit of prostate-specific antigen (PSA) screening remains controversial, new non-invasive biomarkers for prostate carcinoma (PCa) are still required. There is evidence that microRNAs (miRNAs) in whole peripheral blood can separate patients with localized prostate cancer from healthy individuals. However, the potential of blood-based miRNAs for the differential diagnosis of PCa and benign prostatic hyperplasia (BPH) has not been tested. We compared the miRNome from blood of PCa and BPH patients and further investigated the influence of the tumor volume, tumor-node-metastasis (TNM) classification, Gleason score, pretreatment risk status, and the pretreatment PSA value on the miRNA pattern. By microarray approach, we identified seven miRNAs that were significantly deregulated in PCa patients compared to BPH patients. Using quantitative real time PCR (qRT-PCR), we confirmed downregulation of hsa-miR-221* (now hsa-miR-221-5p) and hsa-miR-708* (now hsa-miR-708-3p) in PCa compared to BPH. Clinical parameters like PSA level, Gleason score, or TNM status seem to have only limited impact on the overall abundance of miRNAs in patients' blood, suggesting a no influence of these factors on the expression of deregulated miRNAs.

Indexed as

AgedAged, 80 and overBiomarkers, TumorDiagnosis, DifferentialHumansMaleMicroRNAsMiddle AgedNeoplasm GradingNeoplasm StagingProstate-Specific AntigenProstatic HyperplasiaProstatic NeoplasmsReal-Time Polymerase Chain ReactionTissue Array AnalysisBiomarkers, TumorMicroRNAsProstate-Specific AntigenBenign prostatic hyperplasiaExpression analysisMicroarrayMicroRNAProstate cancer

Identifiers

PMID26831660
OpenAlexW2266501231

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.